Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 1, 2008

View Archived Issues

Ascorbate demonstrates anticancer activity in vitro and in vivo

IL-21 immunologically active in patients with metastatic melanoma, renal cell carcinoma

Johnson & Johnson research into tryptase inhibitors continues with new compounds

PEG coating allows nanoparticles to penetrate the mucus barrier

Immunoglobulin intravenous appears safe over 48 weeks in CIDP patients

S-Methylisothiourea reduces cerebral ischemia damage in vivo

QseC signaling inhibition with LED-209 blocks bacterial vigilance

Novel p38 MAP kinase inhibitors synthesized at Palau Pharma

Growth hormone secretagogue BMS-606056 displays promising preclinical characteristics

Transgene and Roche modify clinical development program for TG-4001/R-3484

Eisai offers Q1 overview

Recent sanofi-aventis patent discloses new analgesic agents

Novel therapeutic agents for glaucoma reported in recent Allergan patents

Arpida submits NDS for intravenous iclaprim in Canada

Recent patents disclose novel antiinfective agents

Overall survival results reported in Erbitux phase III lung cancer study

Shionogi acquires U.S.-based Sciele Pharma

sanofi-aventis acquires Symbion

EMEA approves Intelence for the treatment of HIV

Taxotere Injection approved in Japan for prostate cancer

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...